Renal cell carcinoma and the use of sorafenib
Immunotherapy results in a small overall survival advantage in metastatic renal cell carcinoma (RCC), but there is a need to develop more effective systemic therapies. Angiogenesis has an important role in the pathophysiology of RCC and vascular endothelial growth factor (VEGF) is a key mediator of...
| Main Authors: | , |
|---|---|
| Format: | Online |
| Language: | English |
| Published: |
Dove Medical Press
2006
|
| Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1661649/ |
| id |
pubmed-1661649 |
|---|---|
| recordtype |
oai_dc |
| spelling |
pubmed-16616492008-03-21 Renal cell carcinoma and the use of sorafenib Larkin, James MG Eisen, Tim Review Immunotherapy results in a small overall survival advantage in metastatic renal cell carcinoma (RCC), but there is a need to develop more effective systemic therapies. Angiogenesis has an important role in the pathophysiology of RCC and vascular endothelial growth factor (VEGF) is a key mediator of this process. Sorafenib (BAY 43-9006) is a new agent belonging to a class of drugs called kinase inhibitors and inhibits the VEGF, platelet-derived growth factor (PDGF), and c-KIT receptor tyrosine kinases, amongst others. Sorafenib has shown significant activity with manageable toxicity in metastatic RCC in phase 2 studies in patients pretreated with immunotherapy, whilst prolonged progression-free survival in comparison with placebo in a phase 3 study has been reported. Further phase 3 trials in advanced disease are ongoing and a trial of adjuvant sorafenib therapy in RCC is planned. Dove Medical Press 2006-03 2006-03 /pmc/articles/PMC1661649/ /pubmed/18360584 Text en © 2006 Dove Medical Press Limited. All rights reserved |
| repository_type |
Open Access Journal |
| institution_category |
Foreign Institution |
| institution |
US National Center for Biotechnology Information |
| building |
NCBI PubMed |
| collection |
Online Access |
| language |
English |
| format |
Online |
| author |
Larkin, James MG Eisen, Tim |
| spellingShingle |
Larkin, James MG Eisen, Tim Renal cell carcinoma and the use of sorafenib |
| author_facet |
Larkin, James MG Eisen, Tim |
| author_sort |
Larkin, James MG |
| title |
Renal cell carcinoma and the use of sorafenib |
| title_short |
Renal cell carcinoma and the use of sorafenib |
| title_full |
Renal cell carcinoma and the use of sorafenib |
| title_fullStr |
Renal cell carcinoma and the use of sorafenib |
| title_full_unstemmed |
Renal cell carcinoma and the use of sorafenib |
| title_sort |
renal cell carcinoma and the use of sorafenib |
| description |
Immunotherapy results in a small overall survival advantage in metastatic renal cell carcinoma (RCC), but there is a need to develop more effective systemic therapies. Angiogenesis has an important role in the pathophysiology of RCC and vascular endothelial growth factor (VEGF) is a key mediator of this process. Sorafenib (BAY 43-9006) is a new agent belonging to a class of drugs called kinase inhibitors and inhibits the VEGF, platelet-derived growth factor (PDGF), and c-KIT receptor tyrosine kinases, amongst others. Sorafenib has shown significant activity with manageable toxicity in metastatic RCC in phase 2 studies in patients pretreated with immunotherapy, whilst prolonged progression-free survival in comparison with placebo in a phase 3 study has been reported. Further phase 3 trials in advanced disease are ongoing and a trial of adjuvant sorafenib therapy in RCC is planned. |
| publisher |
Dove Medical Press |
| publishDate |
2006 |
| url |
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1661649/ |
| _version_ |
1611391525554487296 |